News
Apnimed to Participate in Upcoming November Investor Conferences
Nov 6, 2023
Stifel 2023 Healthcare Conference on November 15, 2023, and the 6th Annual Evercore ISI HealthCONx Conference on November 29, 2023.
Apnimed Announces Launch of Joint Venture with Shionogi to Develop Novel Pharmacologic Therapies for Obstructive Sleep Apnea and other Sleep Disorders
Oct 31, 2023
$150M transaction supporting early and clinical-stage pipeline development in OSA and related sleep disorders to find oral pharmacologic solutions for people who cannot use or tolerate current therapies.
Apnimed to Present Recent Data on Investigational Pharmacologic Treatment for Obstructive Sleep Apnea at World Sleep 2023
Oct 18, 2023
Data on AD109 (aroxybutynin/atomoxetine) will be featured in an oral presentation at World Sleep 2023 symposium in Rio de Janeiro, Brazil.
Apnimed to Participate in Upcoming October Investor Conferences
Oct 11, 2023
3rd Annual Needham Private Biotech Company Virtual 1×1 Forum & Leerink Biopharma Private Company Connect (Virtual)
American Journal of Respiratory and Critical Care Medicine Publishes Full, Positive Results of Apnimed’s MARIPOSA Study on AD109, an Investigational Oral Drug for Obstructive Sleep Apnea
Oct 10, 2023
Apnimed announced the publication of the full, clinically-significant results from the MARIPOSA Phase 2b trial in the American Journal of Respiratory and Critical Care Medicine (AJRCCM), a premier journal in pulmonary, critical care and sleep medicine.
Apnimed Adds Independent Director Paul Fonteyne, MS, MBA to Board of Directors
Oct 2, 2023
Fonteyne brings decades of experience in corporate leadership in biopharmaceuticals as well as a track record of commercial success.
Apnimed Announces First Patient Dosed in LunAIRo, the First Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea
Sep 21, 2023
LunAIRo Compares AD109 to Placebo Over 6 and 12 Months
Apnimed Appoints John Yee, MD, MPH, as SVP, Medical Affairs
Sep 18, 2023
Dr. Yee will lead Apnimed’s efforts to engage and inform the clinical community about Apnimed’s lead drug candidate AD109.
Apnimed to Present New Data on Investigational Oral Therapies for Obstructive Sleep Apnea at ERS International Congress 2023
Sep 6, 2023
A post-hoc analysis of data from the MARIPOSA Phase 2b trial will be featured at a poster presentation.
Apnimed to Participate in Upcoming Investor Conferences in September
Aug 30, 2023
Citi 18th Annual BioPharma Conference, Baird Global 2023 Healthcare Conference, and 2023 Cantor Fitzgerald Global Healthcare Conference
GET APNIMED UPDATES
By submitting this form, you are consenting to receive marketing emails from: Apnimed. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact